More recently, HER2-negative invasive BC patients with residual disease after standard anthracycline/taxane NAC regimen were randomized either to 6 cycles of adjuvant ixabepilone (n = 19) or observation (n = 24) [13]. This evidence concerns the gene ERBB2 and breast cancer.